Square Pharmaceuticals (DHA:SQURPHARMA) EV-to-EBITDA : 5.14 (As of Jul. 12, 2025)

Square Pharmaceuticals EV-to-EBITDA Chart

Square Pharmaceuticals Annual Data
	Trend	Mar15	Mar16	Jun17	Jun18	Jun19	Jun20	Jun21	Jun22	Jun23	Jun24
EV-to-EBITDA		Get a 7-Day Free Trial					5.98	7.19	6.42	5.89	5.42

Square Pharmaceuticals Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
EV-to-EBITDA	Get a 7-Day Free Trial															6.01	5.42	6.05	5.71	5.47

Competitive Comparison of Square Pharmaceuticals's EV-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Square Pharmaceuticals's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Square Pharmaceuticals's EV-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Square Pharmaceuticals's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Square Pharmaceuticals's EV-to-EBITDA falls into.

Square Pharmaceuticals EV-to-EBITDA Calculation

Square Pharmaceuticals's EV-to-EBITDA for today is calculated as:

Square Pharmaceuticals's current Enterprise Value is BDT137,933 Mil.
Square Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was BDT26,861 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Square Pharmaceuticals  (DHA:SQURPHARMA) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Square Pharmaceuticals's PE Ratio (TTM) for today is calculated as:

Square Pharmaceuticals's share price for today is BDT209.80.
Square Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was BDT26.517.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).

Please read Which price ratio outperforms the enterprise multiple?

Square Pharmaceuticals EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Square Pharmaceuticals's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Square Pharmaceuticals Business Description